Literature DB >> 14578152

The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years.

Karen G Montgomery1, Dorota M Gertig, Simon W Baxter, Roger L Milne, Gillian S Dite, Margaret R E McCredie, Graham G Giles, Melissa C Southey, John L Hopper, Ian G Campbell.   

Abstract

The HER2 gene controls cellular function and has prognostic significance in breast cancer. The I655V polymorphism was associated with increased risk of breast cancer in Chinese women under the age of 45 years and in women with a first-degree family history of the disease. These associations, however, have not been confirmed in several studies of older women. We conducted a population-based case-control-family study of the I655V polymorphism using 409 Australian women with breast cancer diagnosed before the age of 40 years and 299 controls frequency matched for age. The I655V polymorphism was more common in cases (P = 0.01). A recessive model, in which homozygotes were associated with an adjusted odds ratio of 2.8 (95% confidence interval 1.3-6.2; P = 0.005), gave the best fit under parsimony. Although the biological role of the I655V polymorphism is not known, large independent studies of early onset breast cancer are warranted to attempt to replicate this finding.

Entities:  

Mesh:

Year:  2003        PMID: 14578152

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  11 in total

Review 1.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

2.  ERBB2 genetic polymorphism and breast cancer risk in Chinese women: a population-based case-control study.

Authors:  Shimian Qu; Qiuyin Cai; Yu-Tang Gao; Wei Lu; Hui Cai; Yinghao Su; Shizhen Emily Wang; Xiao-Ou Shu; Wei Zheng
Journal:  Breast Cancer Res Treat       Date:  2007-08-09       Impact factor: 4.872

3.  HER2 Ile655Val polymorphism is negatively associated with breast cancer susceptibility.

Authors:  Felipe Campos de Almeida; Bruna Karina Banin Hirata; Carolina Batista Ariza; Roberta Losi Guembarovski; Karen Brajão de Oliveira; Karen Mayumi Suzuki; Alda Losi Guembarovski; Julie Massayo Maeda Oda; Glauco Akelinghton Freire Vitiello; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2018-02-08       Impact factor: 2.352

4.  HER2Ile655Val Single Nucleotide Polymorphism Associated with Early-Onset Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis.

Authors:  Tung Nguyen Thanh; Bao Song Nguyen Tran; Ai Phuong Hoang Thi; Thang Tran Binh; Thong Ba Nguyen; Tam Le Minh; Quoc Huy Nguyen Vu; Thuan Dang Cong
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

5.  Workgroup report: Implementing a national occupational reproductive research agenda--decade one and beyond.

Authors:  Christina C Lawson; Barbara Grajewski; George P Daston; Linda M Frazier; Dennis Lynch; Melissa McDiarmid; Eisuke Murono; Sally D Perreault; Wendie A Robbins; Megan A K Ryan; Michael Shelby; Elizabeth A Whelan
Journal:  Environ Health Perspect       Date:  2006-03       Impact factor: 9.031

6.  A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer.

Authors:  Stephanie E Nelson; Michael N Gould; John M Hampton; Amy Trentham-Dietz
Journal:  Breast Cancer Res       Date:  2005-03-11       Impact factor: 6.466

7.  Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.

Authors:  Sasha E Stanton; Maureen M Ward; Paul Christos; Rachel Sanford; Christina Lam; Marta V Cobham; Diana Donovan; Ronald J Scheff; Tessa Cigler; Anne Moore; Linda T Vahdat; Maureen E Lane; Ellen Chuang
Journal:  BMC Cancer       Date:  2015-04-11       Impact factor: 4.430

8.  ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancer.

Authors:  Sara Santos; Cláudia S Baptista; Rui M V Abreu; Estela Bastos; Irina Amorim; Ivo G Gut; Fátima Gärtner; Raquel Chaves
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

9.  Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study.

Authors:  Patrick R Benusiglio; Fabienne Lesueur; Craig Luccarini; Donald M Conroy; Mitul Shah; Douglas F Easton; Nick E Day; Alison M Dunning; Paul D Pharoah; Bruce Aj Ponder
Journal:  Breast Cancer Res       Date:  2005-01-12       Impact factor: 6.466

10.  Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies.

Authors:  B Madhu Krishna; Sanjib Chaudhary; Aditya K Panda; Dipti Ranjan Mishra; Sandip K Mishra
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.